C12N 2710/10041
Use of virus, viral particle or viral elements as a vector
C12N2710/10041 (Use of virus, viral particle or viral elements as a vector) appears on 424 US grants and 841 published applications in this corpus.
Search patents in C12N- Granted patents
- 424
- Published applications
- 841
- Assignees
- 400
- Inventors
- 1,439
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 1 |
| 2002 | 4 | 3 |
| 2003 | 3 | 8 |
| 2004 | 2 | 4 |
| 2005 | 4 | 13 |
| 2006 | 1 | 12 |
| 2007 | 2 | 9 |
| 2008 | 6 | 9 |
| 2009 | 4 | 13 |
| 2010 | 4 | 10 |
| 2011 | 4 | 11 |
| 2012 | 3 | 15 |
| 2013 | 4 | 20 |
| 2014 | 13 | 32 |
| 2015 | 19 | 59 |
| 2016 | 30 | 68 |
| 2017 | 36 | 54 |
| 2018 | 39 | 57 |
| 2019 | 34 | 67 |
| 2020 | 37 | 54 |
| 2021 | 37 | 51 |
| 2022 | 34 | 54 |
| 2023 | 21 | 51 |
| 2024 | 30 | 59 |
| 2025 | 31 | 57 |
| 2026 | 18 | 50 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/10043Viral genome or elements thereof as genetic vectorIndexing code323
- C12N 2710/10042Virus or viral particle as vehicleIndexing code27
- C12N 2710/10044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code12
- C12N 2710/10045Special targeting system for viral vectorsIndexing code12
Recent patents
- Combination immunotherapy15 Sep 2026US 12,735,466 B2The Regents of the University of California
- Compositions and methods for recombinant parvovirus production15 Sep 2026US 12,735,724 B2Aavnergene Inc.
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Engineered adenovirus vectors and uses thereof18 Aug 2026US 12,709,761 B2
- Trophin genome editing for treating Duchenne Muscular Dystrophy (DMD)14 Jul 2026US 12,680,100 B2The Trustees of the University of Pennsylvania
- Materials and methods for increasing immune responses within a mammal8 Oct 2026US 2026/0306668 A1Mayo Foundation for Medical Education and Research
- Fusion proteins of il-24 and immunostimulatory cytokines, nk cells expressing il-24 or fusion proteins, and methods of use thereof8 Oct 2026US 2026/0308218 A1Virginia Commonwealth University
- Expression cassette coding for vascular endothelial growth factor8 Oct 2026US 2026/0308618 A1Cornell University
- Compositions and Methods for Increasing AAV Productivity8 Oct 2026US 2026/0308624 A1Oxford Biomedica (US) LLC
- Engineered adenovirus vectors and uses thereof8 Oct 2026US 2026/0308629 A1
Most cited
By later US patents
- Method for the production and purification of adenoviral vectors110US 6,194,191 B1Introgen Therapeutics, Inc. · 2001
- Methods for rapid PEG-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor90US 6,399,385 B1The Trustees of the University of Pennsylvania · 2002
- Adeno associated virus plasmids and vectors62US 9,677,088 B2Oregon Health & Science University · 2017
- Complementing cell lines58US 6,974,695 B2Crucell Holland B. V. · 2005
- Purified adenoviral compositions53US 6,726,907 B1Introgen Therapeutics, Inc. · 2004